IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes

Primary Care Diabetes
Eugene Hughes

Abstract

In type 2 diabetes (T2D), treatment is optimised to minimise hyperglycaemia and the risk of microvascular complications. While there are a number of effective treatments, intensive treatment is associated with negative side effects such as increased hypoglycaemia and weight gain. With complementary modes of action, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and a basal insulin in combination offer an alternative to basal-bolus therapy in T2D. This review describes the rationale behind this treatment combination and presents clinical data available for IDegLira, the first basal insulin (insulin degludec) and GLP-1RA (liraglutide) co-formulation available in one pen for a single injection daily.

References

Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Jan 30, 2007·Current Medical Research and Opinion·Andreas Liebl
Sep 25, 2007·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Feb 18, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Mayer B DavidsonPricilla Hollander
May 10, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Luigi MeneghiniKjeld Hermansen
Apr 18, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·B T BlakV Gimeno
Jul 19, 2012·Clinical Endocrinology·David Russell-Jones, Stephen Gough
Aug 21, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·H W RodbardUNKNOWN BEGIN Once Long trial investigators
Aug 13, 2014·Diabetes Care·John B BuseUNKNOWN NN9068-3912 (DUAL-II) Trial Investigators

❮ Previous
Next ❯

Citations

Mar 25, 2017·Journal of the Science of Food and Agriculture·Aili AierkenMatthias F Melzig
Oct 27, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luciano ZenariAnnunziata Lapolla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.